We are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million ....

August 05, 2026 The Manager, Listing Department BSE Limited The National Stock Exchange of India Ltd. Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051 Dalal Street, Mumbai - 400 001 NSE Symbol: PANACEABIO BSE Scrip Code: 531349 Sub: Receipt of Letter of Award from UNICEF for supply of bivalent Oral Polio Vaccine worth ~US$ 8.205 million in Calendar Year 2028 Reg: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, This is in continuation to our earlier letter dated October 03, 2025, wherein the Company informed that (i) it has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030; and (ii) the total award to the Company was for supply of bOPV in 10 and 20 dose presentation for a period of Q2 CY2026 and CY2027. We are now delighted to inform you that in terms of the aforesaid Long-Term Agreement, the Company has received Letter of Award for supply of bOPV in 10 and 20 dose presentation worth ~US$ 8.205 million (~Rs.78.24 Crore) in Calendar Year 2028. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and other circulars as may be applicable from time to time, is annexed herewith as Annexure A. This is for your kind information and record please. Thanking you, Sincerely yours, For Panacea Biotec Limited Ankit Jain General Manager – Legal & Company Secretary Panacea Biotec Ltd (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com Annexure – A Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 # Particulars Details a. Name of the entity awarding the order(s) / United Nations International Children's contract(s) Emergency Fund (UNICEF) b. Significant terms and conditions of Award for supply of bivalent Oral Polio order(s)/contract(s) awarded in brief Vaccine (bOPV) by Panacea Biotec Limited in Calendar Year 2028 subject to applicable conditions. c. Whether order(s) / contract(s) have been International awarded by domestic / international entity d. Nature of order(s) / contract(s) Supply of bOPV to UNICEF vide Letter of Award received on 04.08.2026 e. Whether domestic or international International f. Time period by which the order(s) / contract(s) Calendar Year 2028 is to be executed g. Broad consideration or size of the order(s) / US$8.205 million (~Rs.78.24 Crore) contract(s) h. Whether the promoter/ promoter group / group No companies have any interest in the entity that awarded the order(s) / contract(s)? If yes, nature of interest and details thereof i. Whether the order(s) / contract(s) would fall No within related party transactions? If yes, whether the same is done at “arm’s length” This is for your kind information and record please. Thanking you, Sincerely yours, For Panacea Biotec Limited Ankit Jain General Manager – Legal & Company Secretary